192705-80-9
192705-80-9 結(jié)構(gòu)式
基本信息
PF-1480232
PD-161570
PF-1480232
1-(tert-Butyl)-3-(6-(2,6-dichlorophenyl)-2-((4-(diethylamino)butyl)amino)pyrido[2,3-d]pyrimidi
1-Tert-butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylaMino-butylaMino)pyrido[2,3-d]pyriMidin-7-yl]urea
N-[6-(2,6-Dichlorophenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea
安全數(shù)據(jù)
常見問題列表
|
FGFR1 39.9 nM (IC 50 ) |
FGFR1 42 nM (Ki) |
FGFR1 autophosphorylation 622 nM (IC 50 ) |
PDGFRβ 262 nM (IC 50 ) |
PDGFR 310 nM (IC 50 ) |
EGFR 240 nM (IC 50 ) |
c-Src 44 nM (IC 50 ) |
TGF-β Receptor
|
PD-161570 (Compound 6c; 0.1-1 μM; 1-8 days; VSMCs) treatment inhibits PDGF-stimulated vascular smooth muscle cell proliferation in a dose dependent fashion with an IC
50
of 0.3 μM on day 8.
PD-161570 suppresses constitutive phosphorylation of the FGF-1 receptor in both human ovarian carcinoma cells (A
121(p)
) and Sf9 insect cells overexpressing the human FGF-1 receptor and blocked the growth of A
121(p)
cells in culture.
PD-161570 can potently inhibit basic fibroblast growth factor (bFGF)-mediated angiogenesis.
Cell Proliferation Assay
| Cell Line: | Vascular smooth muscles cells (VSMCs) |
| Concentration: | 0.1 μM, 0.3 μM, 1 μM |
| Incubation Time: | 1 day, 3 days, 6 days, 8 days |
| Result: | Inhibited VSMC proliferation in a dose dependent fashion with an IC 50 of 0.3 μM at day 8. |